J.P. Morgan Day Three: 2023 Is A Year Of Commercial Challenges

Humira's LOE, Gene Therapy & Alzheimer's Launches Are Major Milestones For 2023

Daily notebook from the J.P. Morgan Healthcare Conference: Gene therapy Vertex enters pricing negotiations on gene therapy, Sanofi sees opportunity in hemophilia despite new gene therapy, and AbbVie raises guidance ahead of the introduction of Humira biosimilars. Plus ICER's Steven Pearson and former Biogen CEO George Scangos weigh in on Alzheimer's developments. 

J.P. Morgan Daily Notebook: Day 3
• Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) president Steven Pearson had positive feedback for Eisai Co., Ltd. on how it communicated the price for its newly approved Alzheimer's medicine Leqembi (lecanemab) to the public, though he said he thinks the $26,500 price set by the company is still too high. ICER is still working on a final assessment, but in the draft assessment ICER determined that Leqembi would be cost effective at an annual list price of $8,500 to $20,600. 

Still, in an interview in San Francisco, Pearson praised Eisai for clearly outlining to the public how it developed the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

More from Advanced Therapies

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.